---
title: "Advanced Biomed Inc. FY 2026: Revenue $127.6K, Net income $6.68M, EPS $5.33— 10-K Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301753331.md"
description: "Advanced Biomed Inc. reported FY2026 results with $127.6K revenue and $6.68M net income, driven by a $14M gain from subsidiary divestitures. The company pivoted from biotech to AI and fintech SaaS via the Acellent acquisition. EPS rose to $5.33 from a $3.18 loss in FY2025."
datetime: "2026-10-13T20:25:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301753331.md)
  - [en](https://longbridge.com/en/news/301753331.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301753331.md)
generator: "portal-rs"
---

# Advanced Biomed Inc. FY 2026: Revenue $127.6K, Net income $6.68M, EPS $5.33— 10-K Summary

Advanced Biomed Inc. reported fiscal 2026 results showing initial revenue of $127637 and net income of $6677077 or diluted earnings per share of $5.33, compared with a net loss of $(3,258,969) and EPS of $(3.18) in FY 2025. FY 2026 results include a $14M gain on disposal of subsidiaries related to the company’s strategic pivot and divestitures.

**Financial Highlights**

-   Revenue: $127,637 for FY 2026, compared with $0 for FY 2025 (initial revenue from Acellent agency services).
-   Net income: $6,677,077 for FY 2026, compared with net loss $(3,258,969) for FY 2025 (FY2026 includes $14.0M gain on disposal of subsidiaries).
-   Diluted EPS: $5.33 for FY 2026, compared with $(3.18) for FY 2025.

**Business Highlights**

-   Strategic pivot from biotechnology to AI and financial algorithmic software completed through divestitures and a refocus of operations.
-   Acquired Acellent in April 2026 and began integrating large language model and fintech SaaS capabilities into core offerings.
-   Generated initial commercial revenue from Acellent agency services as a proof-of-concept, totaling $127,637 for the year.
-   Cost structure shifted away from lab and clinical spend toward cloud infrastructure, data acquisition, and engineering headcount.
-   Management is pursuing near-term monetization via SaaS, predictive analytics and agency channels while monitoring receivable collections to fund operations.

Original SEC Filing: Advanced Biomed Inc. \[ ADVB \] - 10-K - Oct. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ADVB.US](https://longbridge.com/en/quote/ADVB.US.md)

## Related News & Research

- [Advanced Biomed delays annual report filing as audit remains incomplete](https://longbridge.com/en/news/300346092.md)
- [Advanced Biomed Completes AI Acquisition and Leadership Transition](https://longbridge.com/en/news/284946343.md)
- [Amkor (NASDAQ:AMKR) misses Q3 analysts’ revenue estimates](https://longbridge.com/en/news/303129828.md)
- [Oracle Expands AI Software Offerings Ahead of Investor Day](https://longbridge.com/en/news/303115104.md)
- [Tesla-SpaceX Merger Stands at 80%-90% Chance, Dan Ives' $500 Price Tag Explains Why](https://longbridge.com/en/news/303112286.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**